CITIUS ONCOLOGY RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHMon, 06 Apr 2026 23:25:17 +0200https://images.finanzen.net/images/finanzen_net_neu.gifCITIUS ONCOLOGY RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netCitius Oncology präsentierte Bilanzzahlen zum jüngsten JahresviertelSun, 15 Feb 2026 06:35:06 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-praesentierte-bilanzzahlen-zum-juengsten-jahresviertel-15493406Citius Oncology lud am 13.02.2026 zur Finanzkonferenz und hat dort die Zahlen zum am 31.12.2025 abgelaufenen Jahresviertel präsentiert.Der Verlust je Aktie belief sich auf 0,06 USD. Im Vorjahresquartal waren ...

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-praesentierte-bilanzzahlen-zum-juengsten-jahresviertel-15493406SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)Mon, 05 Jan 2026 16:30:00 +0100https://www.finanzen.net/nachricht/aktien/shareholder-alert-purcell-lefkowitz-llp-announces-shareholder-investigation-of-citius-oncology-inc-nasdq-ctor-15392903

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Citius ...

]]>https://www.finanzen.net/nachricht/aktien/shareholder-alert-purcell-lefkowitz-llp-announces-shareholder-investigation-of-citius-oncology-inc-nasdq-ctor-15392903Citius Oncology stellte Ergebnisse des abgelaufenen Quartals vorThu, 25 Dec 2025 06:35:06 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-stellte-ergebnisse-des-abgelaufenen-quartals-vor-15379575Citius Oncology hat am 23.12.2025 Zahlen zum jüngsten Quartal vorgelegt, das am 30.09.2025 endete.Für das Gesamtjahr wurde ein Verlust je Aktie in Höhe von 0,340 USD vermeldet. Im Vorjahr waren -0,310 USD erwirtschaftet ...

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-stellte-ergebnisse-des-abgelaufenen-quartals-vor-15379575Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdateTue, 23 Dec 2025 22:30:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-15377929

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025

Completed $36 million ...

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-15377929Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimThu, 04 Dec 2025 14:37:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-expands-lymphir-distribution-to-turkey-and-middle-east-countries-through-exclusive-agreement-with-er-kim-15335398

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, ]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-expands-lymphir-distribution-to-turkey-and-middle-east-countries-through-exclusive-agreement-with-er-kim-15335398Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)Mon, 01 Dec 2025 18:00:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-announces-u-s-commercial-launch-of-lymphir-a-novel-cancer-immunotherapy-for-cutaneous-t-cell-lymphoma-ctcl-15325971

LYMPHIR now available nationwide

CRANFORD, N.J., Dec. ...

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-announces-u-s-commercial-launch-of-lymphir-a-novel-cancer-immunotherapy-for-cutaneous-t-cell-lymphoma-ctcl-15325971Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual MeetingTue, 25 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-to-exhibit-at-the-67th-american-society-of-hematology-ash-annual-meeting-15311787

Citius Oncology's LYMPHIR™ exhibit will be located at Booth #265

LYMPHIR launch on track for Q4 2025

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-to-exhibit-at-the-67th-american-society-of-hematology-ash-annual-meeting-15311787Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI IntegrationFri, 21 Nov 2025 14:37:00 +0100https://www.finanzen.net/nachricht/aktien/citius-oncology-to-advance-commercial-launch-of-lymphir-with-verix-ai-integration-15304380

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-to-advance-commercial-launch-of-lymphir-with-verix-ai-integration-15304380Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial LaunchMon, 20 Oct 2025 14:37:00 +0200https://www.finanzen.net/nachricht/aktien/citius-oncology-signs-u-s-distribution-agreement-with-mckesson-to-support-lymphir-commercial-launch-15097026

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR

CRANFORD, ...

]]>https://www.finanzen.net/nachricht/aktien/citius-oncology-signs-u-s-distribution-agreement-with-mckesson-to-support-lymphir-commercial-launch-15097026Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 ConferencesFri, 17 Oct 2025 23:00:00 +0200https://www.finanzen.net/nachricht/aktien/citius-pharmaceuticals-and-citius-oncology-to-participate-in-upcoming-october-2025-conferences-15091849

LD Micro Main Event XIX, October 19-21, 2025

2025 Maxim Growth Summit, October 22-23, ...

]]>https://www.finanzen.net/nachricht/aktien/citius-pharmaceuticals-and-citius-oncology-to-participate-in-upcoming-october-2025-conferences-15091849